On the filings, Cencora (COR) is the stronger stock right now — higher on our blended fundamentals-plus-verdict read, and we currently rate it HOLD.
Durable drug distributor compounding revenue ~9%/yr, but flat net income, razor-thin equity and a 34x GAAP P/E leave it fully priced.
Earnings nearly doubled and buybacks are steady, but its multiple on a 0.7%-margin distributor with falling cash flow leaves no room to chase.
| Metric | COR | CAH |
|---|---|---|
| Fundamentals score | 69 | 53 |
| Revenue growth (YoY) | +9.3% | -1.9% |
| Net income growth (YoY) | +3.0% | +83.2% |
| Net margin | 0.5% | 0.7% |
| Return on equity | 103.1% | — |
| ROIC (est.) | 22.6% | — |
| Liabilities / Equity | — | — |
| Piotroski F-score | 5 / 9 | 7 / 9 |
Bold green = the stronger figure. All rows derive from SEC XBRL filings — no market-price data on this page.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 12:06 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 12:08 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.